Replies to post #787028 on NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

No, it is clearly a soft bash. Not the way a long would have written this information.

• Despite the significant therapeutic potential, NWBO faces substantial financial hurdles, marked by recurring operating losses and management's expressed doubt about its ability to continue as a going concern, necessitating continuous reliance on external financing.

“recurring operating losses” this is normal for al pre revenue biotechs - nothing abnormal or surprising here. “management's expressed doubt about its ability to continue as a going concern” more standard boilerplate and not at all what NWBO highlights. They paint a bright future, not a bleak concern about failing in the near future.

• NWBO operates as a niche innovator in a highly competitive oncology market dominated by large pharmaceutical players, banking on its unique, personalized technology to carve out market share while diligently managing regulatory, clinical, and commercialization challenges.

“NWBO operates as a niche innovator” No, it does not. First of all it does not “operate” - it does research and development - it is pre revenue so it does not “operate” in any field as of yet, niche or otherwise. Furthermore, its research and development is not “niche” either. While it is done directly on cases of GBM, it is “tumor agnostic” as the company has stated, and is directly applicable to all or most solid cancers - this is hardly a niche area of research.

“Risks and Outlook: A Path Fraught with Challenges and Potential”

This over emphasizes the “Challenges” and underemphasizes the “Potential.”
He overemphasizes the norm and expected for a pre revenue biotech -
“ recurring operating losses and cash flow deficits. This fundamental financial instability underscores the critical need for continuous and successful equity and/or debt financing. The availability of such funding on favorable terms is not guaranteed, posing a significant threat to the company's long-term viability.” He never mentions how close the expected MAA decision is, or the overwhelming expectation of approval.

“Regulatory approval, particularly for the DCVax-L MAA in the U.K., represents a major near-term catalyst and a substantial risk.”

Again he underemphasizes - why a “substantial risk”? “A positive decision could unlock commercialization” - only “could” unlock not “will” unlock!

“Furthermore, NWBO is actively engaged in a lawsuit against certain market makers, alleging stock manipulation, and is also defending against derivative lawsuits from stockholders. These legal proceedings, while vigorously pursued by the company, consume resources and introduce additional uncertainties.”

It underplays the importance of the court case. And that the case does not consume resources nor introduce additional uncertainties - not at all! It is a model that others will follow to allow the market to operate as it should and not be the personal piggy bank for KG and the like.

CLEARLY A SOFT BASH.